Nuvectis Pharma (NVCT) Short Interest Ratio & Short Volume

Short interest is the volume of Nuvectis Pharma shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 1,480,000 shares of NVCT short. 17.87% of Nuvectis Pharma's shares are currently sold short. Learn More on Nuvectis Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NVCT shares currently have a short interest ratio of 9.0. Learn More on Nuvectis Pharma's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Nuvectis Pharma: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.87% of Nuvectis Pharma's floating shares are currently sold short.

Nuvectis Pharma currently has issued a total of 19,320,000 shares. Some of Nuvectis Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Nuvectis Pharma currently has a public float of 8,280,000 shares.

17.87% of Nuvectis Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Nuvectis Pharma: Alpha Teknova, Inc. (5.93%), SNDL Inc. (1.50%), Entrada Therapeutics, Inc. (7.68%), Kamada Ltd. (0.03%), Mineralys Therapeutics, Inc. (7.89%), Cartesian Therapeutics, Inc. (22.85%), Altimmune, Inc. (32.79%), Mereo BioPharma Group plc (4.40%), ProKidney Corp. (13.00%), Erasca, Inc. (20.66%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

Short selling NVCT is an investing strategy that aims to generate trading profit from Nuvectis Pharma as its price is falling. NVCT shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Nuvectis Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NVCT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NVCT, twice per month. The most recent reporting period available is January, 31 2025.